Harnessing the Full Potential of Therapeutics WithSite-Directed Precise Medicines by Targeting oxMIF
OncoOne takes inspiration from Nobel Laureate Paul Ehrlich’s the “magic bullet” concept and directs modern biomedical research to advance targeted therapeutics for chronic inflammatory and oncological indications.
Our founders have made a groundbreaking discovery: in inflamed tissues and solid tumors the oxidative environment activates the ubiquitously expressed Macrophage Migration Inhibitory Factor (MIF), creating an oxidized MIF isoform, referred to as oxMIF (Thiele, M., Donnelly, S. C. and Mitchell, R. A. (2022)).OxMIF adopts a flexible structure and reveals epitopes usually hidden within the compact MIF trimer. In contrast to its ubiquitous precursor MIF, oxMIF is present only in inflamed or cancerous tissues and thus becomes an invaluable therapeutic target that provides the opportunity to restrict therapeutic activities exclusively to diseased sites.
Focusing on this discovery, we’re developing therapeutic oxMIF-specific antibodies with enormous specificity and selectivity to ensure no interference with the ubiquitous non-pathological MIF.. Besides the therapeutic potential of inhibiting MIF activity in the diseased area, we also explore oxMIF for diagnostic purposes to identify sites of active inflammation and solid tumors.
Our founders have made a groundbreaking discovery: in inflamed tissues and solid tumors the oxidative environment activates the ubiquitously expressed Macrophage Migration Inhibitory Factor (MIF), creating an oxidized MIF isoform, referred to as oxMIF (Thiele, M., Donnelly, S. C. and Mitchell, R. A. (2022)). OxMIF adopts a flexible structure and reveals epitopes usually hidden within the compact MIF trimer. In contrast to its ubiquitous precursor MIF, oxMIF is present only in inflamed or cancerous tissues and thus becomes an invaluable therapeutic target that provides the opportunity to restrict therapeutic activities exclusively to diseased sites.
Focusing on this discovery, we’re developing therapeutic oxMIF-specific antibodies with enormous specificity and selectivity to ensure no interference with the ubiquitous non-pathological MIF. Besides the therapeutic potential of inhibiting MIF activity in the diseased area, we also explore oxMIF for diagnostic purposes to identify sites of active inflammation and solid tumors.
Our founders have made a groundbreaking discovery: in inflamed tissues and solid tumors the oxidative environment activates the ubiquitously expressed Macrophage Migration Inhibitory Factor (MIF), creating an oxidized MIF isoform, referred to as oxMIF (Thiele, M., Donnelly, S. C. and Mitchell, R. A. (2022)). OxMIF adopts a flexible structure and reveals epitopes usually hidden within the compact MIF trimer. In contrast to its ubiquitous precursor MIF, oxMIF is present only in inflamed or cancerous tissues and thus becomes an invaluable therapeutic target that provides the opportunity to restrict therapeutic activities exclusively to diseased sites.
Focusing on this discovery, we’re developing therapeutic oxMIF-specific antibodies with enormous specificity and selectivity to ensure no interference with the ubiquitous non-pathological MIF. Besides the therapeutic potential of inhibiting MIF activity in the diseased area, we also explore oxMIF for diagnostic purposes to identify sites of active inflammation and solid tumors.
OncoOne’s proprietary oxMIF platform merges cutting-edge antibody science with precision targeting—unlocking innovative therapies for cancer and chronic inflammation.
Our pipeline programs ON203 and ON104 are designed to address unmet needs in cancer and chronic inflammation, aiming to improve patient outcomes and daily life.
With its high specificity, our oxMIF platform supports personalized therapies and creates strong potential for co-development partnerships.
